192 related articles for article (PubMed ID: 30055824)
1. Safety, Tolerability, and Pharmacokinetics of Single and Repeat Doses of Nemiralisib Administered via the Ellipta Dry Powder Inhaler to Healthy Subjects.
Wilson R; Jarvis E; Montembault M; Hamblin JN; Hessel EM; Cahn A
Clin Ther; 2018 Aug; 40(8):1410-1417. PubMed ID: 30055824
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the Safety, Tolerability, and Pharmacokinetics of GSK2269557 (Nemiralisib) Administered Via Dry Powder Inhaler to Healthy Japanese Subjects.
Ino H; Wilson R; Terao T; Ogura H; Igarashi H; Cahn A; Numachi Y
Clin Pharmacol Drug Dev; 2019 Jan; 8(1):78-86. PubMed ID: 30303626
[TBL] [Abstract][Full Text] [Related]
3. Safety, Tolerability, and Pharmacokinetics of a New Formulation of Nemiralisib Administered via a Dry Powder Inhaler to Healthy Individuals.
Wilson R; Templeton A; Leemereise C; Eames R; Banham-Hall E; Hessel EM; Cahn A
Clin Ther; 2019 Jun; 41(6):1214-1220. PubMed ID: 31076203
[TBL] [Abstract][Full Text] [Related]
4. An Innovative Approach to Characterize Clinical ADME and Pharmacokinetics of the Inhaled Drug Nemiralisib Using an Intravenous Microtracer Combined with an Inhaled Dose and an Oral Radiolabel Dose in Healthy Male Subjects.
Harrell AW; Wilson R; Man YL; Riddell K; Jarvis E; Young G; Chambers R; Crossman L; Georgiou A; Pereira A; Kenworthy D; Beaumont C; Marotti M; Wilkes D; Hessel EM; Fahy WA
Drug Metab Dispos; 2019 Dec; 47(12):1457-1468. PubMed ID: 31649125
[TBL] [Abstract][Full Text] [Related]
5. Relationship between Pharmacokinetics and Pharmacodynamic Responses in Healthy Smokers Informs a Once-Daily Dosing Regimen for Nemiralisib.
Begg M; Wilson R; Hamblin JN; Montembault M; Green J; Deans A; Amour A; Worsley S; Fantom K; Cui Y; Dear G; Ahmad S; Kielkowska A; Clark J; Boyce M; Cahn A; Hessel EM
J Pharmacol Exp Ther; 2019 Jun; 369(3):337-344. PubMed ID: 30886125
[TBL] [Abstract][Full Text] [Related]
6. A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Investigate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Repeat Doses of Inhaled Nemiralisib in Adults with Persistent, Uncontrolled Asthma.
Khindri S; Cahn A; Begg M; Montembault M; Leemereise C; Cui Y; Hogg A; Wajdner H; Yang S; Robertson J; Hamblin JN; Ludwig-Sengpiel A; Kornmann O; Hessel EM
J Pharmacol Exp Ther; 2018 Dec; 367(3):405-413. PubMed ID: 30217958
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic Comparison of a Unit Dose Dry Powder Inhaler with a Multidose Dry Powder Inhaler for Delivery of Fluticasone Furoate.
Mehta R; Moore A; Riddell K; Joshi S; Chan R
J Aerosol Med Pulm Drug Deliv; 2017 Oct; 30(5):332-338. PubMed ID: 28463040
[TBL] [Abstract][Full Text] [Related]
8. Safety, tolerability, and pharmacokinetics of single and repeat ascending doses of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor: two randomized trials in healthy volunteers.
Mariotti F; Govoni M; Lucci G; Santoro D; Nandeuil MA
Int J Chron Obstruct Pulmon Dis; 2018; 13():3399-3410. PubMed ID: 30425469
[TBL] [Abstract][Full Text] [Related]
9. Drug Interactions for Low-Dose Inhaled Nemiralisib: A Case Study Integrating Modeling, In Vitro, and Clinical Investigations.
Patel A; Wilson R; Harrell AW; Taskar KS; Taylor M; Tracey H; Riddell K; Georgiou A; Cahn AP; Marotti M; Hessel EM
Drug Metab Dispos; 2020 Apr; 48(4):307-316. PubMed ID: 32009006
[TBL] [Abstract][Full Text] [Related]
10. Nemiralisib in Patients with an Acute Exacerbation of COPD: Placebo-Controlled, Dose-Ranging Study.
Fahy WA; Homayoun-Valiani F; Cahn A; Robertson J; Templeton A; Meeraus WH; Wilson R; Lowings M; Marotti M; West SL; Tabberer M; Hessel EM
Int J Chron Obstruct Pulmon Dis; 2021; 16():1637-1646. PubMed ID: 34113095
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics, Safety, and Tolerability of a New Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate Diskus(®) in Healthy Adults.
Vutikullird AB; Gillespie M; Song S; Steinfeld J
J Aerosol Med Pulm Drug Deliv; 2016 Apr; 29(2):207-14. PubMed ID: 26624976
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, Safety, and Tolerability of Tedizolid Phosphate After Single-dose Administration in Healthy Korean Male Subjects.
Kim Y; Kim A; Lee S; Choi SH; Lee DY; Song JS; Lee H; Jang IJ; Yu KS
Clin Ther; 2017 Sep; 39(9):1849-1857. PubMed ID: 28865799
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of Salbutamol Delivered from the Unit Dose Dry Powder Inhaler: Comparison with the Metered Dose Inhaler and Diskus Dry Powder Inhaler.
Moore A; Riddell K; Joshi S; Chan R; Mehta R
J Aerosol Med Pulm Drug Deliv; 2017 Jun; 30(3):164-172. PubMed ID: 28170282
[TBL] [Abstract][Full Text] [Related]
14. An evaluation of the systemic bioavailability of mometasone furoate (MF) after oral inhalation from a MF/formoterol fumarate metered-dose inhaler versus an MF dry-powder inhaler in healthy subjects.
Kosoglou T; Hubbell J; Kantesaria B; Hanson ME; Cutler DL
Clin Pharmacol Drug Dev; 2014 May; 3(3):229-34. PubMed ID: 27128613
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of fluticasone propionate multidose, inhalation-driven, novel, dry powder inhaler versus a prevailing dry powder inhaler and a metered-dose inhaler.
Gillespie M; Song S; Steinfeld J
Allergy Asthma Proc; 2015; 36(5):365-71. PubMed ID: 26314817
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients.
Daley-Yates PT; Mehta R; Chan RH; Despa SX; Louey MD
J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):279-89. PubMed ID: 24074143
[TBL] [Abstract][Full Text] [Related]
17. Tolerability of fluticasone furoate/vilanterol combination therapy in children aged 5 to 11 years with persistent asthma.
Oliver A; VanBuren S; Allen A; Hamilton M; Tombs L; Inamdar A; Kempsford R
Clin Ther; 2014 Jun; 36(6):928-939.e1. PubMed ID: 24793536
[TBL] [Abstract][Full Text] [Related]
18. Safety, pharmacokinetics and dose-response characteristics of GSK2269557, an inhaled PI3Kδ inhibitor under development for the treatment of COPD.
Cahn A; Hamblin JN; Begg M; Wilson R; Dunsire L; Sriskantharajah S; Montembault M; Leemereise CN; Galinanes-Garcia L; Watz H; Kirsten AM; Fuhr R; Hessel EM
Pulm Pharmacol Ther; 2017 Oct; 46():69-77. PubMed ID: 28823947
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of fluticasone propionate and salmeterol delivered as a combination dry powder via a capsule-based inhaler and a multi-dose inhaler.
Mehta R; Daley-Yates PT; Jenkins K; Bianco J; Stylianou A; Louey MD; Chan RH
Pulm Pharmacol Ther; 2014 Oct; 29(1):66-73. PubMed ID: 25035069
[TBL] [Abstract][Full Text] [Related]
20. Ease-of-use preference for the ELLIPTA® dry powder inhaler over a commonly used single-dose capsule dry powder inhaler by inhalation device-naïve Japanese volunteers aged 40 years or older.
Komase Y; Asako A; Kobayashi A; Sharma R
Int J Chron Obstruct Pulmon Dis; 2014; 9():1365-75. PubMed ID: 25525354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
